vs
Side-by-side financial comparison of PCB BANCORP (PCB) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $29.2M, roughly 2.0× PCB BANCORP). On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 11.3%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 10.4%).
PCB Bank is an American community bank that focuses on the Korean-American community based in California and offers commercial banking services. It has branches in 8 states and is the third largest Korean American Bank after Bank of Hope and Hanmi Bank.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
PCB vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $29.2M | $57.3M |
| Net Profit | — | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 45.0% | -82.2% |
| Net Margin | — | -83.0% |
| Revenue YoY | 11.3% | 36.9% |
| Net Profit YoY | — | -9.6% |
| EPS (diluted) | $0.65 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $29.2M | $57.3M | ||
| Q3 25 | $30.4M | $51.3M | ||
| Q2 25 | $29.3M | $48.5M | ||
| Q1 25 | $26.9M | $32.7M | ||
| Q4 24 | $26.2M | $41.8M | ||
| Q3 24 | $25.3M | $33.3M | ||
| Q2 24 | $24.2M | $29.1M | ||
| Q1 24 | $23.9M | $26.0M |
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $11.4M | $-52.9M | ||
| Q2 25 | $9.1M | $-46.6M | ||
| Q1 25 | $7.7M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $7.8M | $-43.6M | ||
| Q2 24 | $6.3M | $-32.3M | ||
| Q1 24 | $4.7M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 45.0% | -82.2% | ||
| Q3 25 | 52.3% | -102.6% | ||
| Q2 25 | 43.3% | -93.4% | ||
| Q1 25 | 40.2% | -143.7% | ||
| Q4 24 | 39.3% | -98.6% | ||
| Q3 24 | 42.2% | -132.0% | ||
| Q2 24 | 36.3% | -139.2% | ||
| Q1 24 | 27.2% | -538.7% |
| Q4 25 | — | -83.0% | ||
| Q3 25 | 37.5% | -103.1% | ||
| Q2 25 | 31.0% | -96.1% | ||
| Q1 25 | 28.8% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | 30.8% | -131.2% | ||
| Q2 24 | 25.9% | -110.9% | ||
| Q1 24 | 19.6% | -544.4% |
| Q4 25 | $0.65 | $-0.73 | ||
| Q3 25 | $0.78 | $-0.82 | ||
| Q2 25 | $0.62 | $-0.75 | ||
| Q1 25 | $0.53 | $-0.81 | ||
| Q4 24 | $0.46 | $-0.71 | ||
| Q3 24 | $0.52 | $-0.73 | ||
| Q2 24 | $0.43 | $-0.55 | ||
| Q1 24 | $0.33 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $207.1M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $390.0M | $139.1M |
| Total Assets | $3.3B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $207.1M | $388.9M | ||
| Q3 25 | $369.5M | $416.1M | ||
| Q2 25 | $263.6M | $291.0M | ||
| Q1 25 | $214.3M | $314.5M | ||
| Q4 24 | $198.8M | $320.6M | ||
| Q3 24 | $193.1M | $298.4M | ||
| Q2 24 | $177.6M | $319.1M | ||
| Q1 24 | $239.8M | $201.2M |
| Q4 25 | $390.0M | $139.1M | ||
| Q3 25 | $384.5M | $148.8M | ||
| Q2 25 | $376.5M | $-11.9M | ||
| Q1 25 | $370.9M | $18.9M | ||
| Q4 24 | $363.8M | $21.7M | ||
| Q3 24 | $362.3M | $11.2M | ||
| Q2 24 | $353.5M | $39.3M | ||
| Q1 24 | $350.0M | $61.6M |
| Q4 25 | $3.3B | $480.2M | ||
| Q3 25 | $3.4B | $506.9M | ||
| Q2 25 | $3.3B | $372.7M | ||
| Q1 25 | $3.2B | $386.7M | ||
| Q4 24 | $3.1B | $392.3M | ||
| Q3 24 | $2.9B | $363.6M | ||
| Q2 24 | $2.9B | $381.8M | ||
| Q1 24 | $2.9B | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.6M | $-25.4M |
| Free Cash FlowOCF − Capex | $24.4M | — |
| FCF MarginFCF / Revenue | 83.6% | — |
| Capex IntensityCapex / Revenue | 7.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $46.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.6M | $-25.4M | ||
| Q3 25 | $16.4M | $-26.6M | ||
| Q2 25 | $4.9M | $-23.3M | ||
| Q1 25 | $2.3M | $-40.4M | ||
| Q4 24 | $39.0M | $-18.8M | ||
| Q3 24 | $11.9M | $-25.2M | ||
| Q2 24 | $14.6M | $-29.1M | ||
| Q1 24 | $8.2M | $-40.7M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $16.2M | — | ||
| Q2 25 | $3.8M | — | ||
| Q1 25 | $1.6M | — | ||
| Q4 24 | $34.9M | — | ||
| Q3 24 | $11.9M | — | ||
| Q2 24 | $12.8M | — | ||
| Q1 24 | $6.0M | — |
| Q4 25 | 83.6% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 13.1% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 133.2% | — | ||
| Q3 24 | 46.8% | — | ||
| Q2 24 | 53.1% | — | ||
| Q1 24 | 25.2% | — |
| Q4 25 | 7.5% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 3.7% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 15.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 7.3% | — | ||
| Q1 24 | 9.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 2.33× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
